STAGE III RENAL CELL CANCER AJCC V8
Clinical trials for STAGE III RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could a Pre-Surgery drug shrink kidney tumors?
Disease control OngoingThis phase 2 trial tests whether the drug cabozantinib can shrink tumors in patients with locally advanced kidney cancer before they undergo surgery. The study includes 22 participants with clear cell renal cell carcinoma. Researchers will measure how many patients respond to the…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 23, 2026 11:54 UTC
-
Could a superfruit boost immunotherapy for kidney cancer?
Disease control OngoingThis early-stage trial tests adding camu camu, a prebiotic fruit, to standard immunotherapy drugs (nivolumab and ipilimumab) for people with advanced kidney cancer that has spread. The goal is to see if camu camu is safe and can help the immune system fight cancer better. About 3…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New hope for rare kidney cancer: drug combo shows promise
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer growth) and nivolumab (which helps the immune system fight cancer)—works better than nivolumab alone for a rare kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial includes about …
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 22, 2026 12:04 UTC
-
New hope for kidney cancer: which drug combo works best after immunotherapy fails?
Disease control OngoingThis study tests two different drug treatments in people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of lenvatinib and everolimus or cabozantinib alone. The goal is to see w…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with locally advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks before their operation. The go…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug targets Hard-to-Treat cancers with rare gene flaw
Disease control OngoingThis study tests a drug called adavosertib in adults with advanced solid tumors that have a missing or broken SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:07 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis study tests whether adding the targeted therapy cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will receive either the usual treatment or the usual …
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:05 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Matched conditions: STAGE III RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:04 UTC